Status:
UNKNOWN
Characterizing Rheumatoid Arthritis With 68Ga-FAPI PET/CT
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Arthritis
Eligibility:
All Genders
18-90 years
Phase:
EARLY_PHASE1
Brief Summary
68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation, such as IgG4-related disease and infla...
Detailed Description
Arthritis is a term used to mean any disorder that affects the joints. The two most common forms of arthritis are osteoarthritis and rheumatoid arthritis.Rheumatoid arthritis is an autoimmune chronic ...
Eligibility Criteria
Inclusion
- suspected or confirmed untreated arthritis patients;
- 18F-FDG PET/CT within two weeks;
- signed written consent.
Exclusion
- pregnancy;
- breastfeeding;
- known allergy against FAPI
- any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04514614
Start Date
September 1 2020
End Date
December 1 2022
Last Update
January 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730